Skip to content

A multicenter clinical study on the treatment of intraventricular hemorrhage by neuroendoscopic hematoma removal combined with external ventricular drainag

A multicenter clinical study on the treatment of intraventricular hemorrhage by neuroendoscopic hematoma removal combined with external ventricular drainag

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073710
Enrollment
Unknown
Registered
2023-07-19
Start date
2023-07-19
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral hemorrhage

Interventions

Neuroendoscopic treatment group:Neuroendoscopic surgery
External ventricular drainage group:External ventricular drainage

Sponsors

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Over 18 years old and under 80 years old; 2. Upon admission, head imaging confirmed ventricular hemorrhage with a volume greater than 10ml and symptoms of acute obstructive hydrocephalus; 3. The patient did not have other malignant diseases;

Exclusion criteria

Exclusion criteria: 1 Patients who could not receive complete follow-up; 2 Pregnant women and women trying to become pregnant during the follow-up period; 3. Rupture of intracranial arteriovenous malformations, choroidal plexus malformations, moyamoya disease or tumors (treatment of existing aneurysms or intracranial tumors) 4. Complicated subtentorial hemorrhage 5. Intracerebral hematoma cannot be steadily enlarged within the treatment time window 6. Persistent internal bleeding in the retroperitoneal area or gastrointestinal tract, multifocal and superficial bleeding in the genitourinary system or respiratory tract. 7. The disease is not expected to survive to 180 days due to the diagnosis of malignant tumors, etc

Design outcomes

Primary

MeasureTime frame
mRS;

Secondary

MeasureTime frame
IVH;GCS;

Countries

China

Contacts

Public ContactXU HAO

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

xuhao021@ustc.edu.cn+86 180 1957 6586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026